HEADER CHAPERONE 21-AUG-12 4B7P TITLE STRUCTURE OF HSP90 WITH NMS-E973 INHIBITOR BOUND COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN, RESIDUES 9-236; COMPND 5 SYNONYM: HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA ANTIGEN COMPND 6 NY-REN-38; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 511693; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BL21; SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PET15 KEYWDS ATPASE, CHAPERONE, ATP-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR G.FOGLIATTO,L.GIANELLINI,M.G.BRASCA,E.CASALE,D.BALLINARI,M.CIOMEI, AUTHOR 2 A.DEGRASSI,A.DE PONTI,M.GERMANI,M.GUANCI,M.PAOLUCCI,P.POLUCCI, AUTHOR 3 M.RUSSO,F.SOLA,B.VALSASINA,C.VISCO,F.ZUCCOTTO,D.DONATI,E.FELDER, AUTHOR 4 A.GALVANI,E.PESENTI,S.MANTEGANI,A.ISACCHI REVDAT 2 17-JUL-13 4B7P 1 JRNL REVDAT 1 29-MAY-13 4B7P 0 JRNL AUTH G.FOGLIATTO,L.M.GIANELLINI,M.G.BRASCA,E.CASALE,D.BALLINARI, JRNL AUTH 2 M.CIOMEI,A.DEGRASSI,A.DE PONTI,M.GERMANI,M.GUANCI, JRNL AUTH 3 M.PAOLUCCI,P.POLUCCI,M.RUSSO,F.SOLA,B.VALSASINA,C.VISCO, JRNL AUTH 4 F.ZUCCOTTO,D.DONATI,E.FELDER,E.PESENTI,S.MANTEGANI, JRNL AUTH 5 A.GALVANI,A.ISACCHI JRNL TITL NMS-E973, A NOVEL SYNTHETIC INHIBITOR OF HSP90 WITH JRNL TITL 2 ACTIVITY IN MODELS OF DRUG RESISTANCE TO TARGETED AGENTS, JRNL TITL 3 INCLUDING INTRACRANIAL METASTASES. JRNL REF CLIN.CANCER RES. V. 19 3520 2013 JRNL REFN ISSN 1078-0432 JRNL PMID 23674492 JRNL DOI 10.1158/1078-0432.CCR-12-3512 REMARK 2 REMARK 2 RESOLUTION. 1.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.6.0117 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30.34 REMARK 3 DATA CUTOFF (SIGMA(F)) : NULL REMARK 3 COMPLETENESS FOR RANGE (%) : 98.28 REMARK 3 NUMBER OF REFLECTIONS : 22969 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.17549 REMARK 3 R VALUE (WORKING SET) : 0.17426 REMARK 3 FREE R VALUE : 0.19720 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.1 REMARK 3 FREE R VALUE TEST SET COUNT : 1228 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.700 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.744 REMARK 3 REFLECTION IN BIN (WORKING SET) : 1564 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 97.13 REMARK 3 BIN R VALUE (WORKING SET) : 0.206 REMARK 3 BIN FREE R VALUE SET COUNT : 93 REMARK 3 BIN FREE R VALUE : 0.278 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1688 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 33 REMARK 3 SOLVENT ATOMS : 160 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.106 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.098 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.058 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.701 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.954 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.946 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 1750 ; 0.014 ; 0.020 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2360 ; 1.866 ; 1.986 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 213 ; 5.596 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 79 ;36.965 ;25.443 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 323 ;12.818 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 7 ;23.757 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 266 ; 0.127 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1297 ; 0.009 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.20 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN USED IF PRESENT IN REMARK 3 THE INPUT U VALUES REFINED INDIVIDUALLY REMARK 4 REMARK 4 4B7P COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 21-AUG-12. REMARK 100 THE PDBE ID CODE IS EBI-53822. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 12-FEB-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-2 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.87 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD (MX-225) REMARK 200 DETECTOR MANUFACTURER : MARRESEARCH REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 24199 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.70 REMARK 200 RESOLUTION RANGE LOW (A) : 30.00 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.3 REMARK 200 DATA REDUNDANCY : 4 REMARK 200 R MERGE (I) : 0.04 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.00 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.80 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.9 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : 0.20 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.48 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.18 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 22.02100 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLY A 7 REMARK 465 PRO A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 465 VAL A 230 REMARK 465 SER A 231 REMARK 465 ASP A 232 REMARK 465 ASP A 233 REMARK 465 GLU A 234 REMARK 465 ALA A 235 REMARK 465 GLU A 236 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 94 44.80 -109.21 REMARK 500 ALA A 166 -148.63 68.63 REMARK 500 ARG A 182 142.63 -170.46 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE 9UN A1226 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY REMARK 900 -BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL REMARK 900 )-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6YLAMINE REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 REMARK 900 -TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN REMARK 900 -6-YLAMINE REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR REMARK 900 BINDING TO HSP90 ISOFORMS REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING REMARK 900 DOMAIN REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN REMARK 900 PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN REMARK 900 LIGASE REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- REMARK 900 PYRAZOL-3-YL)-BENZENE-1,2-DIOL REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- REMARK 900 4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID REMARK 900 ETHYLAMIDE REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- REMARK 900 METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3- REMARK 900 YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H64 REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H71 REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE REMARK 900 FRAGMENT REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO REMARK 900 AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC REMARK 900 PYRAZOLE, ISOXAZOLE AMIDE ANALOGS REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHX RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJG RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJJ RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XK2 RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YE2 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE3 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE4 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE5 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE6 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE7 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE8 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE9 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEA RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEB RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEC RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YED RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEE RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEF RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEG RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEH RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEI RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEJ RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YI0 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI5 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI6 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI7 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YJW RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YJX RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK2 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YK9 RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKB RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKC RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKE RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKI RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 2YKJ RELATED DB: PDB REMARK 900 TRICYCLIC SERIES OF HSP90 INHIBITORS REMARK 900 RELATED ID: 4AIF RELATED DB: PDB REMARK 900 AIP TPR DOMAIN IN COMPLEX WITH HUMAN HSP90 PEPTIDE REMARK 900 RELATED ID: 4AWO RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED REMARK 900 INHIBITORS REMARK 900 RELATED ID: 4AWP RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED REMARK 900 INHIBITORS REMARK 900 RELATED ID: 4AWQ RELATED DB: PDB REMARK 900 COMPLEX OF HSP90 ATPASE DOMAIN WITH TROPANE DERIVED REMARK 900 INHIBITORS REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE FIRST TWO RESIDUES GP ARE EXPRESSION TAG DBREF 4B7P A 9 236 UNP P07900 HS90A_HUMAN 9 236 SEQADV 4B7P GLY A 7 UNP P07900 EXPRESSION TAG SEQADV 4B7P PRO A 8 UNP P07900 EXPRESSION TAG SEQRES 1 A 230 GLY PRO ASP GLN PRO MET GLU GLU GLU GLU VAL GLU THR SEQRES 2 A 230 PHE ALA PHE GLN ALA GLU ILE ALA GLN LEU MET SER LEU SEQRES 3 A 230 ILE ILE ASN THR PHE TYR SER ASN LYS GLU ILE PHE LEU SEQRES 4 A 230 ARG GLU LEU ILE SER ASN SER SER ASP ALA LEU ASP LYS SEQRES 5 A 230 ILE ARG TYR GLU SER LEU THR ASP PRO SER LYS LEU ASP SEQRES 6 A 230 SER GLY LYS GLU LEU HIS ILE ASN LEU ILE PRO ASN LYS SEQRES 7 A 230 GLN ASP ARG THR LEU THR ILE VAL ASP THR GLY ILE GLY SEQRES 8 A 230 MET THR LYS ALA ASP LEU ILE ASN ASN LEU GLY THR ILE SEQRES 9 A 230 ALA LYS SER GLY THR LYS ALA PHE MET GLU ALA LEU GLN SEQRES 10 A 230 ALA GLY ALA ASP ILE SER MET ILE GLY GLN PHE GLY VAL SEQRES 11 A 230 GLY PHE TYR SER ALA TYR LEU VAL ALA GLU LYS VAL THR SEQRES 12 A 230 VAL ILE THR LYS HIS ASN ASP ASP GLU GLN TYR ALA TRP SEQRES 13 A 230 GLU SER SER ALA GLY GLY SER PHE THR VAL ARG THR ASP SEQRES 14 A 230 THR GLY GLU PRO MET GLY ARG GLY THR LYS VAL ILE LEU SEQRES 15 A 230 HIS LEU LYS GLU ASP GLN THR GLU TYR LEU GLU GLU ARG SEQRES 16 A 230 ARG ILE LYS GLU ILE VAL LYS LYS HIS SER GLN PHE ILE SEQRES 17 A 230 GLY TYR PRO ILE THR LEU PHE VAL GLU LYS GLU ARG ASP SEQRES 18 A 230 LYS GLU VAL SER ASP ASP GLU ALA GLU HET 9UN A1226 33 HETNAM 9UN 5-[2,4-DIHYDROXY-6-(4-NITROPHENOXY)PHENYL]-N- HETNAM 2 9UN (1-METHYLPIPERIDIN-4-YL)-1,2-OXAZOLE-3- HETNAM 3 9UN CARBOXAMIDE FORMUL 2 9UN C22 H22 N4 O7 FORMUL 3 HOH *160(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 GLU A 42 ASP A 66 1 25 HELIX 3 3 PRO A 67 ASP A 71 5 5 HELIX 4 4 THR A 99 LEU A 107 1 9 HELIX 5 5 GLY A 114 ALA A 124 1 11 HELIX 6 6 ASP A 127 GLY A 135 5 9 HELIX 7 7 VAL A 136 TYR A 139 5 4 HELIX 8 8 SER A 140 VAL A 144 1 5 HELIX 9 9 GLU A 192 LEU A 198 5 7 HELIX 10 10 GLU A 199 SER A 211 1 13 SHEET 1 AA 8 GLU A 18 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 TYR A 160 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 SITE 1 AC1 21 ASN A 51 ALA A 55 LYS A 58 ASP A 93 SITE 2 AC1 21 ILE A 96 GLY A 97 MET A 98 ASP A 102 SITE 3 AC1 21 ASN A 106 LEU A 107 LYS A 112 GLY A 135 SITE 4 AC1 21 HIS A 154 THR A 184 VAL A 186 HOH A2050 SITE 5 AC1 21 HOH A2055 HOH A2061 HOH A2092 HOH A2110 SITE 6 AC1 21 HOH A2120 CRYST1 52.746 44.042 53.621 90.00 115.59 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.018959 0.000000 0.009079 0.00000 SCALE2 0.000000 0.022706 0.000000 0.00000 SCALE3 0.000000 0.000000 0.020678 0.00000